Close



Mar 5, 2024 04:02PM
Dec 20, 2023 08:01AM
Dec 20, 2023 08:00AM
Nov 9, 2023 04:02PM
Sep 18, 2023 08:03AM
Sep 18, 2023 08:00AM
Aug 14, 2023 04:02PM TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 11, 2023 08:04AM
Jul 11, 2023 08:00AM
Jun 20, 2023 08:03AM
Jun 20, 2023 08:00AM
May 30, 2023 08:00AM
May 10, 2023 04:02PM
Apr 25, 2023 07:42AM TRACON Pharmaceutical (TCON) Announces Arbitration Award in Dispute with I-Mab (IMAB)
Apr 25, 2023 07:41AM
Mar 8, 2023 04:02PM
Dec 14, 2022 08:02AM
Dec 14, 2022 08:00AM
Nov 21, 2022 08:00AM
Nov 14, 2022 04:02PM
Oct 6, 2022 08:04AM TRACON Pharmaceutical (TCON) Announces Independent Data Monitoring Committee Recommends ENVASARC Phase 2 Trial to Proceed as Planned
Oct 6, 2022 08:00AM
Sep 14, 2022 08:00AM
Sep 14, 2022 08:00AM
Aug 30, 2022 05:59AM
Aug 29, 2022 08:00PM
Aug 29, 2022 08:00PM
Aug 29, 2022 08:02AM TRACON Pharmaceutical (TCON) Granted FDA Approval of IND for CTLA-4 Antibody YH001
Aug 29, 2022 08:00AM
Aug 10, 2022 04:02PM
Aug 8, 2022 08:02AM
Aug 8, 2022 08:00AM
Jul 26, 2022 08:05AM
May 11, 2022 04:02PM
Apr 19, 2022 08:13AM TRACON Pharmaceutical (TCON) Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
Apr 19, 2022 08:05AM
Mar 15, 2022 04:03PM
Mar 15, 2022 04:02PM
Mar 10, 2022 08:05AM
Mar 10, 2022 08:05AM
Feb 2, 2022 08:05AM
Dec 27, 2021 08:00AM TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
Nov 29, 2021 08:06AM
Nov 29, 2021 08:05AM
Nov 3, 2021 04:02PM
Oct 11, 2021 08:00AM
Aug 11, 2021 04:02PM
Jul 20, 2021 08:05AM
Jun 29, 2021 08:06AM TRACON Pharmaceutical (TCON) Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma
Jun 29, 2021 08:05AM

251,633 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All